Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
- SEAVUE Study Group
- Icahn School of Medicine at Mount Sinai
- Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Janssen Pharmaceutical Companies of Johnson & Johnson
- Janssen Scientific Affairs, LLC
- Université Paris Cité
- Vita-Salute San Raffaele University
- Northwestern University
- Western University
- Hemato-Oncology
- University of Pennsylvania
- Mayo Clinic Rochester, MN
- Semmelweis University
- University of Calgary
- New York Presbyterian Hospital
- City Hospital 31
- University of California at San Diego
Research output: Contribution to journal › Article › peer-review
284
Scopus
citations